Share Prices & Company Research

Market News

18 Nov 2024 | 14:04

ValiRx subsidiary makes first sale

(Sharecast News) - ValiRx, a life science company focussed on early-stage cancer therapeutics and women's health, announced the first sale from its wholly-owned subsidiary Inaphaea BioLabs on Monday. The AIM-traded firm said the shipment included patient-derived cells (PDCs), part of Inaphaea's new Assay Ready Reagents (ARR) product line.

It said the ARR range allowed customers to perform assays directly without requiring in-house cell cultivation, streamlining research workflows.

While the financial value of the initial order was said to not be material, the board said the sale represented a key milestone in validating Inaphaea's offering and providing a potential revenue stream for ValiRx.

"This first sale of our new product range is a major milestone for our commercialisation efforts," said chief executive officer Mark Eccleston.

At 1158 GMT, shares in ValiRx were up 23.13% at 1.69p.

Reporting by Josh White for Sharecast.com.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new portfolio or transferring your portfolio from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.